The first 24-hour bilirubin level as a predictor of hyperbilirubinemia in healthy term newborns

Rina Triasih, MD; Ekawaty L Haksari, MD; Achmad Surjono, MD

ABSTRACT
Background Early discharging healthy term newborns results in a difficulty to recognize hyperbilirubinemia.
Objective The aim of this study was to determine the value of the first 24-hour total and unbound bilirubin levels in predicting hyperbilirubinemia in healthy term newborns.
Methods The first 24-hour and the 5th day total and unbound bilirubin levels were measured in 84 healthy term newborns. The total bilirubin level was measured spectrophotometrically, whereas unbound bilirubin level was determined by peroxidase-oxidation method. Hyperbilirubinemia was defined as serum total bilirubin of ≥12.9 mg/dL or serum unbound bilirubin of ≥0.5 mg/dL after 24 hours of life.
Results A correlation between the first 24-hour and the 5th day total bilirubin levels was found (r= 0.53) with a regression equation: Y (total bilirubin on day 5) = 4.69 + 1.15X (total bilirubin in the first 24 hours). In unbound bilirubin (r=0.31), the regression equation was Y (unbound bilirubin on day 5) = 0.13 + 0.95X (unbound bilirubin in the first 24-hours). The relative risk for developing hyperbilirubinemia in newborns whose TB₁ was ≥4.5 mg/dL was 12 (95% CI 2.9;48.4), whereas newborns whose UB₁ was ≥0.09 mg/dL was 9.5 (95% CI 1.2;77.4).
Conclusion Total bilirubin level of ≥4.5 mg/dL in the first 24 hours can predict the development of hyperbilirubinemia in term newborns in the first week of life. Newborns with such level of total bilirubin need a longer stay or should visit the hospital on day 5-7

Keywords: first day bilirubin level, neonatal hyperbilirubinemia

The tendency to early discharge healthy term newborns is now increasing because of some medical, social, and economic reasons. Some studies reported that early discharge is related to a risk of hospital readmission, and that the most common cause of readmission during the early neonatal period is hyperbilirubinemia. Visual recognition in estimating the jaundice severity is inaccurate and varies with the level of training of the nurses, resident physicians and attending staffs. Moreover, asking mothers to observe their infants for the development of jaundice is not accountable; it may be difficult for some parents to recognize significant jaundice. Thus, it is difficult to recognize, follow-up, and perform early treatment of hyperbilirubinemia as the result of early newborn hospital discharge. The danger of failing to recognize and treat neonatal hyperbilirubinemia following early discharge had been confirmed by reports of kernicterus in full-term healthy newborns with no apparent hemolysis, without jaundice in the first 24 hours, and no cause for hyperbilirubinemia. Therefore early identification of newborns at risk for developing severe hyperbilirubinemia and possible bilirubin-induced neurologic dysfunction has become a necessity. The practice parameter for the management of hyperbilirubinemia in the healthy newborn infant published in 1994 by the American Academy of Pediatrics recommended that a serum bilirubin examination should be done in any infants noted to have the tendency to early discharge healthy term newborns.
be jaundiced by visual assessment in the first 24 hours after birth. It also stated that follow-up by a healthcare professional should be scheduled within 2 to 3 days for all neonates discharged less than 48 hours after birth. The need for measurement of serum bilirubin at follow-up depends on the judgment of the professional providing care, based on his or her visual estimation of the severity of jaundice. Unfortunately, unless the visual estimation of the severity of jaundice is fairly accurate and there is a concern about its intensity, bilirubin levels can rise to a dangerous level.

Recent studies suggested that determining total serum bilirubin in the first 24 hours of life could help to recognize infants at risk. However, in the management of neonatal hyperbilirubinemia, the concentration of total bilirubin is not specifically significant to predict the brain damage due to bilirubin toxicity. An association between unbound bilirubin and kernicterus had been discussed in several studies. The aim of the present study was to prospectively determine the ability of the first 24-hour total and unbound bilirubin levels (TB and UB) to predict hyperbilirubinemia in term healthy newborns in the first week of life.

Methods

The study was performed in the newborn nursery of the Sardjito General Hospital, Yogyakarta, from December 2000 to March 2001. All healthy full-term (37-42 weeks of gestation as determined by Dubowitz score) and appropriate for gestational age newborns (based on the Indonesian intrauterine weight growth curve) and with an Apgar score of more than 6, were prospectively enrolled in the study. Infants with sepsis, ABO incompatibility, signs of hemolytic tendencies, or had no complete TB and UB measurements, were excluded from the study. Informed consents were obtained from the parents. All subjects were cared with the rooming-in method to ensure the practice of exclusive breastfeeding.

Hematocrit (Hct), total bilirubin (TB), and unbound bilirubin (UB) levels were initially measured within the first 24 hours of life (Hct, TB, UB) and were repeated on the 5th day (Hct, TB, UB). In some, earlier measurement were performed (Hct, TB, UB) for clinical reasons (clinical jaundice Kramer III-V before day 5). Parents whose infants were discharged early, were suggested to visit the lactation clinic in the outpatient department on the 5th day, or as soon as their infants appeared jaundiced. Gender, birth weight, gestational age, maternal age, delivery route, Apgar scores, rupture of the membranes, and feeding pattern were recorded in all subjects.

Capillary blood samples were drawn by heel stick for checking the levels of Hct, TB, and UB. In order to avoid the influence of light, care was taken by covering the serum collecting tubes with aluminum foil. An amount of 20 mL of serum was required for the TB and UB measurements. TB level was measured spectrophotometrically and UB level was determined by peroxidase-oxidation method at room temperature of 30°C using UB-analyzer UAF-2 (Arrows Co Ltd., Osaka). Newborns with TB level of ≥12.9 mg/dL or UB level of ≥0.5 mg/dL after 24 hours of life were defined as having hyperbilirubinemia, and they had to undergo phototherapy if their TB level was ≥20 mg/dL or UB level was ≥0.7 mg/dL on follow up.

Data were statistically analyzed with the independent sample t test and X2 analysis for comparison of the clinical data between the hyperbilirubinemia and non-hyperbilirubinemia groups. The critical TB and UB levels with high sensitivity and high specificity were determined with the receiver operating characteristic (ROC) curve analysis. The correlations between TB and UB for all enrolled infants were found by the linear regression analysis. The relative risks with 95% confidence interval (CI) were calculated to find out the risk of hyperbilirubinemia among the newborns whose TB or UB exceeded the critical levels.

Results

Of the 84 infants enrolled in this study, 20 (24%) had TB ≥12.9 mg/dL and 6 (7%) had UB ≥0.5 mg/dL. The distribution of the maternal and neonatal categorical characteristics and the incidence of hyperbilirubinemia according to each variable are presented in Table 1. There was no significant difference between subjects that developed and did not develop hyperbilirubinemia in respect to various factors that may be associated
with the risk of hyperbilirubinemia, such as hematocrit level, gestational age, birth weight, delivery mode, maternal age, rupture of the membranes, and feeding pattern.

**Figure 1** and **2** showed the correlation between the first 24-hour TB/UB and the 5th day TB/UB. There was a correlation between TB₁ and TB₅ levels (r=0.53) with a regression equation as Y (TB₅) = 4.69 + 1.15 X (TB₁). For unbound bilirubin (r=0.31), the regression equation was Y (UB₅) = 0.13 + 0.95 X (UB₁).

By ROC analysis, the level of TB₁ of ≥4.5 mg/dL was determined to have a high sensitivity (90.0%) and a high specificity (71.9%), whereas the level of UB₁ of ≥0.09 mg/dL had a sensitivity of 83.3% and a specificity of 69.2% to predict newborns who would develop hyperbilirubinemia (**Figure 3** and **4**).

The relative risk for developing hyperbilirubinemia in newborns whose TB₁ was ≥4.5 mg/dL was 12 (95% CI 2.9;48.4), whereas newborns whose UB₁ was ≥0.09 mg/dL was 9.5 (95% CI 1.2;77.4). The mean of TB₁ in the infants who developed hyperbilirubinemia was significantly higher than that in the infants who did not develop hyperbilirubinemia, but the mean of UB₁ between the hyperbilirubinemia and non-hyperbilirubinemia infants was not significantly different (**Table 2**).

**Discussion**

In this study the first 24-hour and the 5th day total and unbound bilirubin levels in healthy term newborns were analyzed. Measurement of unbound bilirubin level which was specific enough to predict the brain damage caused by bilirubin toxicity was the strength of the present study. However, the limited period of

**Table 1. The Characteristics of Hyperbilirubinemia and Non-Hyperbilirubinemia Subjects**

<table>
<thead>
<tr>
<th></th>
<th>Hyperbilirubinemia (+)</th>
<th>Hyperbilirubinemia (-)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n = 20</td>
<td>n = 64</td>
</tr>
<tr>
<td>Hematocrit day 1 (%)*</td>
<td>58.6</td>
<td>56.5</td>
</tr>
<tr>
<td>Hematocrit day 5 (%)*</td>
<td>54.14</td>
<td>51.5</td>
</tr>
<tr>
<td>Gestational age (wk)*</td>
<td>38.82</td>
<td>39.00</td>
</tr>
<tr>
<td>Birth weight (g)*</td>
<td>2947.73</td>
<td>2940.49</td>
</tr>
<tr>
<td>Vaginal delivery †</td>
<td>14</td>
<td>48</td>
</tr>
<tr>
<td>Breastfed†</td>
<td>19</td>
<td>55</td>
</tr>
<tr>
<td>Maternal age (years)*</td>
<td>28.35</td>
<td>28.81</td>
</tr>
<tr>
<td>Rupture of membranes (hr)*</td>
<td>9.41</td>
<td>11.72</td>
</tr>
</tbody>
</table>

* values are given as mean  
† values are given as number of infants
follow up and not daily total and unbound bilirubin measurements were the weakness of our study.

Seidman et al.\textsuperscript{12} found that the critical bilirubin level of 5 mg/dL was reported to have a high specificity (91.9\%) and low sensitivity (45.5\%) for detecting hyperbilirubinemia; the positive predictive value was very low (8.9\%) and the negative predictive value was very high (99\%). In another study, the bilirubin level of ≥6 mg/dL in the first day had sensitivity of 97.9\% and positive and negative predictive value of 90\% and 26.2\%, respectively.\textsuperscript{11} A similar study found that no infant whose bilirubin level was < 5 mg/dL at 20-28 hours of life developed hyperbilirubinemia, whereas 33\% of those whose bilirubin level was ≥8 mg/dL developed hyperbilirubinemia.\textsuperscript{16} Our findings showed that a total bilirubin level of ≥4.5 mg/dL in the first 24 hours of life had high sensitivity (90\%) and specificity (71.9\%), with positive and negative predictive value of 50\% and 96.8\%, respectively. These differences may be attributable to ethnic and geographic variations in different populations and laboratory variability in the measurement of bilirubin.

Newborns whose total bilirubin level was ≥4.5 mg/dL in the first 24 hours had higher risk of developing hyperbilirubinemia than those whose total bilirubin level was < 4.5 mg/dL (RR=12; 95% CI 2.9; 48.4). In Alpay's study,\textsuperscript{11} of the 206 newborns whose bilirubin level was ≥6 mg/dL in the first 24 hours of life, 26.2\% developed hyperbilirubinemia, whereas only 2.0\% of the 292 newborns, whose bilirubin level were <6 mg/dL in the first day of life, developed hyperbilirubinemia (RR = 12.8).

Some previous studies\textsuperscript{17-19} showed that breast feeding is related to hyperbilirubinemia, but the others\textsuperscript{20,21} found different results. Some probable factors associated with breast milk jaundice may include the presence of pregnandiol in the breastmilk,\textsuperscript{22} inhibition of glucuronyl-transferase enzyme by long chain fatty acid in the breast milk,\textsuperscript{23} increased concentration of lipoprotein lipase in breast milk that inhibited bilirubin conjugation,\textsuperscript{24} or increased enteric absorption of unconjugated bilirubin due to inadequate intake.\textsuperscript{18,19,22} However, the certain mechanism of hyperbilirubinemia in the breastfed infants is still unclear, whether it is

<table>
<thead>
<tr>
<th>Table 2. The TB\textsubscript{1} and UB\textsubscript{1} Levels of Hyperbilirubinemia and Non-Hyperbilirubinemia Subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperbilirubinemia ((+)) &amp; Hyperbilirubinemia ((-)) &amp; P &amp; 95%CI</td>
</tr>
<tr>
<td>TB\textsubscript{1} (mg/dL) &amp; 6.06 ± 2.05 &amp; 3.70 ± 1.59 &amp; 0.000 &amp; 1.50; 3.24</td>
</tr>
<tr>
<td>UB\textsubscript{1} (mg/dL) &amp; 0.14 ± 0.07 &amp; 0.08 ± 0.07 &amp; 0.068 &amp; 0.004; 0.11</td>
</tr>
</tbody>
</table>

Values are given as mean ± standard deviation.
related to inadequate intake or the role of specific substances in the breast milk. Almost all of the infants who developed or did not develop hyperbilirubinemia in the present study were given breast milk during hospitalization, and at home. It supports the dictum that there is no reason for not giving breast milk because of the fear of developing hyperbilirubinemia.

Several recent reports5-8 showed that kernicterus occasionally occurs in healthy breast or bottle-fed infants, born at or near term, and in the absence of any diagnosed complicating factors such as isoimmunization or other causes of hemolysis, prematurity, sepsis or any constitutional defects in hepatic bilirubin clearance. It has been suggested that unbound bilirubin is responsible in causing brain damage with its toxicity to membranes of either brain capillary endothelium or neurons in the form of bilirubin acid.13

In the present study we also evaluated the value of the first 24 hours unbound bilirubin level in predicting hyperbilirubinemia in healthy term newborns. Although our study showed that unbound bilirubin level of \( \geq 0.09 \) mg/dL in the first 24 hours of life had high sensitivity and moderate specificity (83.3% and 69.2%, respectively), the difference of the first 24 hours unbound bilirubin level in hyperbilirubinemic and non-hyperbilirubinemic infants was not significant. It suggests that we could not use the first 24 hours unbound bilirubin level as a predictor of hyperbilirubinemia in term newborns. These findings also showed that in term newborns, the unbound bilirubin level did not always match the total bilirubin level. Surjono25 found 4 groups of infants, i.e., low total bilirubin-low unbound bilirubin, relatively high total bilirubin-low unbound bilirubin, high total bilirubin-high unbound bilirubin, and low total bilirubin-relatively high unbound bilirubin. The level of unbound bilirubin is related to the bilirubin binding capacity of serum albumin. This binding is influenced by the serum bilirubin level and albumin level, pH, the presence of substances that occupy bilirubin’s binding sites on albumin, such as drugs (i.e., aspirin and sulfonamide), fatty acids in nutritional products (e.g., Intralipid®), asphyxia, sepsis, hypothermia, and hypoglicemia.22 In healthy term newborns, the bilirubin-albumin binding capacity is still appropriate.

Ninety percent of healthy term newborns in the study that developed hyperbilirubinemia could be predicted by total bilirubin level of 4.5 mg/dL in the first 24 hours of life. A 96.8% negative predictive value in our study also suggests that measurement of total bilirubin level in the first 24 hours of life can help to identify newborns that are unlikely to require further evaluation and intervention. We suggested that newborns with total bilirubin level of \( \geq 4.5 \) mg/dL in the first 24 hours, should stay longer in the nursery or must visit the hospital on day 5-7.

Based on the findings in the present study, we concluded that a total bilirubin level of 4.5 mg/dL in the first 24 hours of life will predict nearly all healthy term newborns that will develop hyperbilirubinemia in the first week of life, whereas unbound bilirubin level could not be used as a predictor of hyperbilirubinemia. However, the results of this study are applicable only to healthy term newborns and further studies including larger number of newborns and longer follow up should be carried out.

References